Key facts
- It has raised $4.8M across 1 recorded rounds; the latest was Seed Round ($4.8M) in Aug 2025.
- Notable investors include Gaingels, Alpaca VC, Blu Venture Investors, Redbud VC, Flyover Capital — 9 tracked in total.
- Trially has filed 1 Form D with the SEC, most recently Aug 2025 ($4.8M sold to 13 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Trially
Funding rounds
1 roundsAbout Trially
Developer of an AI-powered clinical trial recruitment platform designed to streamline clinical research and catalyze advanced therapies. The company's platform enables trial sites with functionality to support business development, feasibility, and automate patient searching and recruitment list generation across all sites and all studies, and has proven to multiply enrollment rates and enhance site efficiency, enabling companies to focus their team on their impact work and bring life-saving drugs to patients faster.
- Sector
- Healthcare
- HQ
- Kansas City, MO, United States
- Founded
- 2023
- Employees
- 2
- Website
- trially.ai/
- Ownership
- Privately Held (backing)
Trially doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Trially shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Trially in its N-PORT filings yet. We sweep new filings monthly.